<DOC>
	<DOCNO>NCT01307007</DOCNO>
	<brief_summary>The primary objective study assess safety investigational intravenous iron ( ferric carboxymaltose [ FCM ] ) equal dose iron dextran explore mechanism hypophosphatemia follow administration FCM equal dose iron dextran treat woman iron deficiency anemia due heavy uterine bleeding ( HUB ) .</brief_summary>
	<brief_title>Hypophosphatemia With Intravenous Ferric Carboxymaltose Versus Iron Dextran Women With Iron Deficiency Secondary Heavy Uterine Bleeding</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Uterine Hemorrhage</mesh_term>
	<mesh_term>Hypophosphatemia</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Iron-Dextran Complex</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<criteria>Female subject &gt; = 18 year age History Heavy Uterine Bleeding within past 6 month Screening visit central laboratory Hgb &lt; 12 g/dL Screening Visit ferritin &lt; = 100 ng/mL &lt; = 300 TSAT &lt; = 30 % Demonstrate ability understand requirement study , willingness abide study restriction return required assessment Known hypersensitivity reaction component ferric carboxymaltose iron dextran Previously randomize clinical study ferric carboxymaltose Requires dialysis treatment chronic kidney disease Chronic kidney disease , mark estimate glomerular filtration rate &lt; 60 ml/min/1.73m square Previous kidney transplant History primary hypophosphatemic disorder Hypophosphatemia &lt; 2.6 mg/dl No evidence iron deficiency During 10 day period prior screen treat intravenous iron During 30 day period prior screen study period treat erythropoiesis stimulate agent ( ESA ) regimen label During 30 day period prior screen study period treat red blood cell transfusion , radiotherapy and/or chemotherapy During 30 day period prior screen study period require surgical procedure necessitate general anesthesia Any nonviral infection Aspartate aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) screening , determined central lab , great 1.5 time upper limit normal Known positive hepatitis evidence active disease Received investigational drug within 30 day screen Alcohol drug abuse within past 6 month Hemochromatosis iron storage disorder Malignancy history within past 5 year basal squamous cell skin cancer Any laboratory abnormality , medical condition psychiatric disorder opinion investigator would put subject 's disease management risk may result subject unable comply study requirement Pregnant sexuallyactive female subject childbearing potential willing use acceptable form contraception Untreated primary hyperparathyroidism Untreated gastrointestinal malabsorption ( e.g. , sprue )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>